coming in to sell marijuana, have you jersey folkn commercial real estate that are seeing as a pharma economy, we learned from other states we're not going to be we're headed to this we will legalize. >> it >> i don't see it. >> it is going to happen. >> he congress to look at this. hislawmakers in democratic not a done deal. bill: so, fresh, cran ber cannabis? >> nothing that can replace tom. bill: fair enough. >> all right, thank you, scott, appreciate it. luck, you got a t ahead. >> got it. bill: not too much don't agree, but. >> let's check out headlines we're chasing tonight. >> new york city looking to open up safi jec -- safe-inject sites. philadelphia is already seeking out said operators establish safe sites, oprah winfrey speect of buzz about her potential for. in style magazine said that oprah has no plans to run, say it is not something that interests me, i don't have the dna for it. >> can you make a horse return home, a deputy videotaped animal running down the road, he pleads for the animal to stop. >> stop, fleece. please. >> the horse was returned to its owner. >> and yankees

number this is not some cyclical smokestack play that is expected to raise numbers when economy is booming. pharma outfits almost never pull extra dollar per share a lot of it comes from the fact that business is very strong cfo bill chase explained on the conference call, rummira is growing. -- that is up 28% from just last year and abbvie sees hepatitis c business doubling. and mega ret is there new hep c cure abbvie is the kind of drug stock that is worth buying as it goes lower. it is an opportunity even if the new initiative from jeff bassos seems to be a serious threat companies like abbvie should be fine stocks being pulled down because of etfs. etfs created to mimic all of the drug stocks and get away with single stock risk. biotech focuses on neurological conditions autoimmune diseases the guidance was so good it sent the stock surging. biogen rallied. you are almost getting the latest numbers for free. biogen's headlines results were much on to write home about. still posted a 19 cent earnings miss management guidance was excellent. in these context of these quarter quarterly reports. bi

pharma sector, including some of the demographic -- core domestic plays and then -- >> okay. >> -- look at a fedex which is behaving almost like a tech stock for reasons that are specific to this company and the economy's while it's had a move is a name you can stay with. >> all right guy, i noticed your financials did pretty well today. >> yeah, they did. listen to the montage, tim and i were just listening, one guy said he was so bullish he couldn't stand up or sit down or something, makes me want to go sti sell everything. because the unanimity with people who are bullish, people are tripping over themselves to say how much more bullish can i be than the next guy you know what, sometimes the crowd is right i think that's a situation that we find ourselves in so i still think the financials work i think based on price to book value, they still have runway to the upside i think these defense stocks, which have just been on fire, ever since then-candidate obama, president obama, was elected, those things have quadrupled in some cases i think they still work. industrials, i mean, i throw fedex in from to a certain extent names like honeywell, roper, boeing to a certain extent, the industrials are stil